137 related articles for article (PubMed ID: 29099380)
1. [Consensus on castration-resistant prostate cancer management in Spain.].
Alcaraz A; Martínez-Piñeiro L; Rodríguez A; Rubio J; Borque Á; Burgos J; Carballido J; Cózar JM; Crespo I; Esquena S; Gómez-Veiga F; López D; Miñana B; Morote J; Ribal MJ; Solsona E; Suárez JF; Unda M
Arch Esp Urol; 2017 Nov; 70(9):777-791. PubMed ID: 29099380
[TBL] [Abstract][Full Text] [Related]
2. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
[TBL] [Abstract][Full Text] [Related]
3. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
5. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.
Maluf F; Soares A; Avanço G; Hada AL; Cardoso APG; Carneiro A; Herchenhorn D; Jardim DLF; Schutz FA; Kater FR; Pereira FMT; Monteiro FSM; Morbeck IAP; Reolon JFN; da Trindade KM; Andrade LMQDS; Nogueira LM; Furoni R; Natel RA; Dos Reis RB; Fogace RN; Souza VC
Int Braz J Urol; 2021; 47(2):359-373. PubMed ID: 33284538
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
Kamoto T
Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
[TBL] [Abstract][Full Text] [Related]
8. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
9. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations for follow up in castration resistant prostate cancer.].
Vázquez-Alonso F; Puche-Sanz I; Cózar-Olmo JM
Arch Esp Urol; 2018 Sep; 71(8):735-742. PubMed ID: 30319133
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
[TBL] [Abstract][Full Text] [Related]
12. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
13. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
14. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F
Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
[TBL] [Abstract][Full Text] [Related]
15. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
18. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
20. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]